Pharmaceutical
Formulation
Development.
Overcoming poor solubility and bioavailability challenges.
Expertise
Our Leadership team has extensive collective experience in steering products from pre-clinical to commercial manufacture.
Science-led
Our approach is scientific, collaborative and open, ensuring an open dialogue and transparency that fits your project.
Award-winning
We are a leading CDMO recognised for numerous awards including a King's Award For Enterprise.
Nimble
We adapt to your project needs, and pledge to never relegating it to the bottom of the list.
We have extensive drug formulation development experience taking research projects from early proof of concept and feasibility through scale-up and onto clinical manufacture for oral, nasal and pulmonary dosage forms.
Collaborative and science-led
Our approach to formulation development.
We work closely with clients from the start, defining project aims and understanding the target product profile. Early development includes pre-formulation activities and excipient selection to create the ideal dosage form. Throughout, we focus on formulation suitability, scale-up potential, and commercialization. Stability studies and extensive analytical techniques ensure product quality.
Once a formulation is ready, we scale the process in our pilot plant, equipped to mirror our GMP facility, ensuring confidence before clinical manufacture.
Dosage Form Development
Experts in oral, nasal and pulmonary formulation development.
Oral dosage forms
- Blending, dry granulation, milling, coating
- Tablets (IR, MR, SR, Minitabs)
- Capsules (API, Powder blend, lipid)
- Small molecules, biologics, NCEs
- Grams to 250Kg batch sizes
Nasal and Pulmonary dosage forms
- (Nasal) Powder and liquid dosage forms
- (Pulmonary) powder
- Spray drying intermediates, micronization, lipids
- Capsule filling, device filling
- Blister packaging
Pharmaceutical Spray Drying
Overcoming poor solubility and bioavailability formulation challenges.
We’re specialists in the use of pharmaceutical spray drying to improve the solubility and bioavailability of your formulation, helping to enhance the dissolution rate and stability.
UpperSolv™ development platform
Identifying a successful formulation strategy.
Our early formulation platform, UpperSolv™ outlines a parallel integrated formulation and biopharmaceutical screening protocol that can rapidly compare a range of enabling formulation strategies that can be translated into clinical processes and products.
Frequently Asked Questions
Can you support formulation development across multiple dosage forms?
Yes, we offer end-to-end formulation development across a range of dosage forms, including oral solids and liquids, nasal liquids and powders, pulmonary liquids and powders, and sterile dosage forms.
What experience do you have with complex or challenging APIs (e.g., poorly soluble)?
We specialise in working with challenging APIs, including those with low solubility, poor permeability, or chemical instability. Our scientists leverage a wide range of enabling technologies, such as spray drying to overcome these barriers. We tailor our approach to each molecule, ensuring optimal performance and patient outcomes.
How do you ensure the stability and bioavailability of a drug formulation?
We prioritise both stability and bioavailability from the earliest stages of formulation development. We conduct comprehensive pre-formulation studies to understand the physicochemical properties of the API. Stability is assessed through ICH-compliant stability studies under various conditions to ensure the formulation remains effective and safe throughout its shelf life.
Get in touch
If you’re looking to work with a CDMO that is flexible and nimble, then we’re here to help.
Speak to our team to discuss your requirements.
Useful Resources
Step inside Upperton’s R&D labs
Take a tour of our labs with Laura Mason as she shares how our integrated team supports a wide range of projects, from proof of concept to clinical manufacture.
video
